We have located links that may give you full text access.
A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes.
KI Reports 2021 March
AIM: Preclinical studies suggest treatment of metabolic acidosis may slow chronic kidney disease (CKD) progression. This systematic review aimed to summarize evidence from randomized controlled trials (RCTs) concerning the benefits and risks of bicarbonate therapy on kidney outcomes.
METHODS: Medline, EMBASE, and Cochrane databases were searched for RCTs with ≥3 months' follow-up in patients with CKD (estimated glomerular filtration rate [eGFR] ≤60 ml/min per 1.73 m2 and/or proteinuria) comparing the effects of sodium bicarbonate with placebo/no study medication on kidney outcomes. The primary outcome was change from baseline to last measurement in kidney function measured as either eGFR or creatinine clearance. Treatment effects were summarized using random-effects meta-analysis.
RESULTS: Fifteen trials (2445 participants, median follow-up 12 months) were eligible for inclusion. Compared with placebo or no study medication, sodium bicarbonate retarded the decline in kidney function (standardized mean difference [SMD]: 0.26; 95% confidence interval [CI]: 0.13-0.40; I 2 = 50%, low certainty evidence), and reduced the risk of end-stage kidney failure (risk ratio [RR]: 0.53; 95% CI 0.32-0.89; I 2 = 69%, low certainty evidence). The effect of sodium bicarbonate on proteinuria (SMD: -0.09; 95% CI -0.27 to 0.09; I 2 = 28%, very low certainty evidence), systolic blood pressure (weighted mean difference [WMD]: -0.57 mm Hg; 95% CI -2.32 to 1.18; I 2 = 0%, low certainty evidence), all-cause death (RR: 0.81; 95% CI: 0.39-1.68; I 2 = 30%; very low certainty evidence) and edema (RR: 1.16; 95% CI: 0.90-1.50; I 2 = 28%; low certainty evidence) were uncertain.
CONCLUSION: Sodium bicarbonate may slow CKD progression. Adequately powered randomized trials are required to evaluate the benefits and risks of sodium bicarbonate in CKD.
METHODS: Medline, EMBASE, and Cochrane databases were searched for RCTs with ≥3 months' follow-up in patients with CKD (estimated glomerular filtration rate [eGFR] ≤60 ml/min per 1.73 m2 and/or proteinuria) comparing the effects of sodium bicarbonate with placebo/no study medication on kidney outcomes. The primary outcome was change from baseline to last measurement in kidney function measured as either eGFR or creatinine clearance. Treatment effects were summarized using random-effects meta-analysis.
RESULTS: Fifteen trials (2445 participants, median follow-up 12 months) were eligible for inclusion. Compared with placebo or no study medication, sodium bicarbonate retarded the decline in kidney function (standardized mean difference [SMD]: 0.26; 95% confidence interval [CI]: 0.13-0.40; I 2 = 50%, low certainty evidence), and reduced the risk of end-stage kidney failure (risk ratio [RR]: 0.53; 95% CI 0.32-0.89; I 2 = 69%, low certainty evidence). The effect of sodium bicarbonate on proteinuria (SMD: -0.09; 95% CI -0.27 to 0.09; I 2 = 28%, very low certainty evidence), systolic blood pressure (weighted mean difference [WMD]: -0.57 mm Hg; 95% CI -2.32 to 1.18; I 2 = 0%, low certainty evidence), all-cause death (RR: 0.81; 95% CI: 0.39-1.68; I 2 = 30%; very low certainty evidence) and edema (RR: 1.16; 95% CI: 0.90-1.50; I 2 = 28%; low certainty evidence) were uncertain.
CONCLUSION: Sodium bicarbonate may slow CKD progression. Adequately powered randomized trials are required to evaluate the benefits and risks of sodium bicarbonate in CKD.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app